Supplemental Digital Content 3

A

$\text{Peak thrombin (nM)}$

Dabigatran $\text{Berplex (IU/mL)}$

B

$\text{Peak (nM thrombin)}$

Dabigatran $\text{NovoSeven (nM)}$

C

$\text{Peak thrombin (nM)}$

Dabigatran $\text{Octaplex (IU/mL)}$

$\text{No Dabigatran}$

$\text{Dabigatran 625 ng/mL}$

$\text{Dabigatran 200 ng/mL}$

$\text{Dabigatran 1000 ng/mL}$
Fig. 1. The effect of increasing doses of CFC on peak thrombin generation and lag time in human platelet-poor plasma spiked with dabigatran. (A) Beriplex, (B) NovoSeven, (C), Octaplex, (D) FEIBA, (E) Profiline and (F) Bebulin. Data represent mean ± SE (n = 5 per group). *P < 0.05 vs. control (untreated plasma), dotted line. †P < 0.05 vs. dabigatran 200 ng/mL, no CFC. ‡P < 0.05 vs. dabigatran 600 ng/mL, no CFC.
CFC = Coagulation factor concentrate; FEIBA = Factor Eight Inhibitor Bypassing Activity.